Vor Biopharma Inc. Variable Lease, Cost
Vor Biopharma Inc. (VOR) reported Variable Lease, Cost of $67.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-11
- Vor Biopharma Inc. variable lease, cost for the quarter ending 2026-06-30 was $67.00K, a 91.34% decline year-over-year.
- Vor Biopharma Inc. variable lease, cost for the quarter ending 2026-03-31 was $59.00K, a 91.70% decline year-over-year.
- Vor Biopharma Inc. variable lease, cost for the quarter ending 2025-12-31 was $95.00K, a 87.55% decline year-over-year.
- Vor Biopharma Inc. variable lease, cost for the quarter ending 2025-09-30 was $57.00K, a 91.63% decline year-over-year.
- Vor Biopharma Inc. variable lease, cost for fiscal 2025 was $1.64M, a 38.30% decline from fiscal 2024.
- Vor Biopharma Inc. variable lease, cost for fiscal 2024 was $2.65M, a 1.34% increase from fiscal 2023.
- Vor Biopharma Inc. variable lease, cost for fiscal 2023 was $2.62M, a 45.61% increase from fiscal 2022.
- Vor Biopharma Inc. variable lease, cost for fiscal 2022 was $1.80M, a 63.60% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $67.00K 10-Q · filed 2026-08-11 | $126.00K 10-Q · filed 2026-08-11 | $221.00K derived: sum of 3 quarters · filed 2026-08-11 | $278.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $59.00K 10-Q · filed 2026-05-13 | $154.00K derived: sum of 2 quarters · filed 2026-05-13 | $211.00K derived: sum of 3 quarters · filed 2026-05-13 | $985.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $152.00K derived: sum of 2 quarters · filed 2026-03-30 | $926.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.64M 10-K · filed 2026-03-30 |
| 2025-09-30 | $57.00K 10-Q · filed 2025-11-13 | $831.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.54M 10-Q · filed 2025-11-13 | $2.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $774.00K 10-Q · filed 2026-08-11 | $1.49M 10-Q · filed 2026-08-11 | $2.25M derived: sum of 3 quarters · filed 2026-08-11 | $2.93M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $711.00K 10-Q · filed 2026-05-13 | $1.47M derived: sum of 2 quarters · filed 2026-05-13 | $2.15M derived: sum of 3 quarters · filed 2026-05-13 | $2.83M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $763.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.44M derived: sum of 2 quarters · filed 2026-03-30 | $2.12M derived: sum of 3 quarters · filed 2026-03-30 | $2.65M 10-K · filed 2026-03-30 |
| 2024-09-30 | $681.00K 10-Q · filed 2025-11-13 | $1.36M derived: sum of 2 quarters · filed 2025-11-13 | $1.89M 10-Q · filed 2025-11-13 | $2.59M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $679.00K 10-Q · filed 2025-08-12 | $1.21M 10-Q · filed 2025-08-12 | $1.91M derived: sum of 3 quarters · filed 2025-08-12 | $2.57M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $530.00K 10-Q · filed 2025-05-14 | $1.23M derived: sum of 2 quarters · filed 2025-05-14 | $1.89M derived: sum of 3 quarters · filed 2025-05-14 | $2.55M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $697.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.36M derived: sum of 2 quarters · filed 2025-03-20 | $2.02M derived: sum of 3 quarters · filed 2025-03-20 | $2.62M 10-K · filed 2025-03-20 |
| 2023-09-30 | $663.00K 10-Q · filed 2024-11-07 | $1.32M derived: sum of 2 quarters · filed 2024-11-07 | $1.92M 10-Q · filed 2024-11-07 | $2.51M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $661.00K 10-Q · filed 2024-08-08 | $1.26M 10-Q · filed 2024-08-08 | $1.85M derived: sum of 3 quarters · filed 2024-08-08 | $2.41M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $597.00K 10-Q · filed 2024-05-09 | $1.19M derived: sum of 2 quarters · filed 2024-05-09 | $1.75M derived: sum of 3 quarters · filed 2024-05-09 | $2.05M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $589.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $1.16M derived: sum of 2 quarters · filed 2024-03-20 | $1.46M derived: sum of 3 quarters · filed 2024-03-20 | $1.80M 10-K · filed 2024-03-20 |
| 2022-09-30 | $567.00K 10-Q · filed 2023-11-07 | $868.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.21M 10-Q · filed 2023-11-07 | $1.53M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $301.00K 10-Q · filed 2023-08-10 | $642.00K 10-Q · filed 2023-08-10 | $965.00K derived: sum of 3 quarters · filed 2023-08-10 | $1.31M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $341.00K 10-Q · filed 2023-05-11 | $664.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.01M derived: sum of 3 quarters · filed 2023-05-11 | $1.32M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $665.00K derived: sum of 2 quarters · filed 2023-03-23 | $977.00K derived: sum of 3 quarters · filed 2023-03-23 | $1.10M 10-K · filed 2023-03-23 |
| 2021-09-30 | $342.00K 10-Q · filed 2022-11-10 | $654.00K derived: sum of 2 quarters · filed 2022-11-10 | $776.00K 10-Q · filed 2022-11-10 | $921.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $312.00K 10-Q · filed 2022-08-11 | $434.00K 10-Q · filed 2022-08-11 | $579.00K derived: sum of 3 quarters · filed 2022-08-11 | $580.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $122.00K 10-Q · filed 2022-05-12 | $267.00K derived: sum of 2 quarters · filed 2022-05-12 | $268.00K derived: sum of 3 quarters · filed 2022-05-12 | $309.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $146.00K derived: sum of 2 quarters · filed 2022-03-14 | $187.00K derived: sum of 3 quarters · filed 2022-03-14 | $235.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $1.00K 10-Q · filed 2021-11-10 | $42.00K derived: sum of 2 quarters · filed 2021-11-10 | $90.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $41.00K 10-Q · filed 2021-08-09 | $89.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $48.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |